公开(公告)号：EP2943792B1

公开(公告)日：2018-11-14

申请号：EP14700091.3

申请日：2014-01-07

申请人： SphingoTec GmbH

发明人： BERGMANN, Andreas

IPC分类号： G01N33/574

CPC分类号： G01N33/57488 ,  G01N33/57415 ,  G01N33/57423 ,  G01N33/74 ,  G01N2333/62 ,  G01N2333/70 ,  G01N2410/00

摘要： Subject matter of the present invention is a method for predicting the risk of getting cancer in a subject that does not suffer from cancer or alternatively diagnosing cancer in a subject comprising: determining the level of Pro-Tachykinin, its splice variants or fragments thereof including Substance P and Neurokinin of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Tachykinin, its splice variants or fragments thereof with a risk for getting cancer, wherein a reduced level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein an reduced level is correlated with the diagnosis of cancer.

公开(公告)号：EP3309550A1

公开(公告)日：2018-04-18

申请号：EP16193587.9

申请日：2016-10-12

申请人： sphingotec GmbH

发明人： Bergmann, Andreas

IPC分类号： G01N33/543

CPC分类号： G01N33/54393 ,  G01N2333/775 ,  G01N2800/2821

摘要： The present invention provides a method for the detection of Apolipoprotein E isotype 4 (ApoE4) or fragments thereof in a blood sample of a subject, whereby said method comprises the steps of contacting said sample with a solid phase, contacting said sample with at least one binder binding specifically to ApoE4 or a fragment thereof, thereby forming an ApoE4binder-complex, and detecting the ApoE4-binder-complex.

摘要翻译： 本发明提供了检测受试者血液样品中的载脂蛋白E同种型4（ApoE4）或其片段的方法，由此所述方法包括以下步骤：使所述样品与固相接触，使所述样品与至少一种 结合剂特异性结合ApoE4或其片段，从而形成ApoE4结合剂复合物，并检测ApoE4-结合剂复合物。

公开(公告)号：EP3052941A1

公开(公告)日：2016-08-10

申请号：EP14777609.0

申请日：2014-09-30

申请人： SphingoTec GmbH

发明人： BERGMANN, Andreas ,  NG, Leong

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N2333/47 ,  G01N2800/324 ,  G01N2800/56

摘要： Disclosed is a method for predicting the risk of getting a major adverse cardiac event or death in a subject that has suffered an acute myocardial infarction containing determining the level of Protachykinin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from the subject; and correlating the level of Protachykininor fragments thereof with the a risk for getting a major adverse cardiac event or death, wherein an elevated level is predictive for an enhanced risk of getting a major adverse cardiac event or death.

摘要翻译： 公开了一种用于预测在患有急性心肌梗塞的受试者中获得主要不良心脏事件或死亡的风险的方法，所述急性心肌梗死包括测定从受试者获得的体液中至少5个氨基酸的Protachykinin或其片段的至少5个氨基酸 ; 并且将Protachykininor片段的水平与获得主要的不良心脏事件或死亡的风险相关联，其中升高的水平预示出获得主要不良心脏事件或死亡的风险增加。

公开(公告)号：EP3002589A1

公开(公告)日：2016-04-06

申请号：EP15187839.4

申请日：2015-10-01

申请人： sphingotec GmbH

发明人： BERGMANN, Andreas ,  MELANDER, Olle

IPC分类号： G01N33/574 ,  G01N33/74

CPC分类号： G01N33/74 ,  G01N33/6893 ,  G01N2800/362

摘要： Subject matter of the present invention is a method for stratifying a female subject for hormone replacement therapy comprising:
• determining the level of Pro-Neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said female subject; and
• comparing said level of Pro-Neurotensin or fragments thereof with a pre-determined pro-NT threshold and
• wherein in case the determined level of Pro-Neurotensin or fragments thereof is above said pre-determined threshold then the subject is identified as having an enhanced risk to suffer an adverse event or having an enhanced risk to attract a disease in case of a hormone replacement therapy, and
• wherein in case the determined level of Pro-Neurotensin or fragments thereof is below said pre-determined threshold then the subject is identified as not having an enhanced risk to suffer an adverse event or as not having an enhanced risk to attract a disease in case of a hormone replacement therapy, and/or
• determining the level of Pro-Enkephalin or fragments thereof of at least 5 amino acids (pENK) in a bodily fluid obtained from said female subject; and
• comparing said level of Pro-Enkephalin or fragments thereof with a pre-determined "pENK threshold" and
• wherein in case the determined level of Pro-Enkephalin or fragments thereof is below said pre-determined pENK threshold then the subject is identified as having an enhanced risk to suffer an adverse event or having an enhanced risk to attract a disease in case of a hormone replacement therapy, and
• wherein in case the determined level of Pro-Enkephalin or fragments thereof is above said pre-detennined pENK threshold then the subject is identified as not having an enhanced risk to suffer an adverse event or as not having an enhanced risk to attract a disease in case of a hormone replacement therapy.

摘要翻译： 本发明的主题是用于分层雌激素替代疗法的雌性受试者的方法，包括：确定从所述雌性受试者获得的体液中至少5个氨基酸的Pro-Neurotensin或其片段的水平; 并且将所述Pro-Neurotensin或其片段的水平与预先确定的亲NT阈值和¢相比较，其中如果所确定的Pro-Neurotensin或其片段的水平高于所述预定阈值，则识别所述受试者 因为在激素替代治疗的情况下，具有增加的风险以遭受不良事件或增加吸引疾病的风险，而如果所确定的Pro-Neurotensin或其片段的水平低于所述预定阈值， 那么该受试者被鉴定为不具有增加的风险，以承受不良事件或在激素替代疗法的情况下不具有增强的吸引疾病的风险，和/或确定前脑啡肽或其片段的水平 在从所述女性受试者获得的体液中至少5个氨基酸（pENK）; 并且将所述Pro-Enkephalin或其片段的水平与预先确定的“pENK阈值”和“¢”进行比较，其中如果所确定的Pro-脑啡肽或其片段的水平低于所述预先确定的pENK阈值，则所述对象是 被鉴定为在激素替代治疗的情况下具有增加的风险以遭受不良事件或增加吸引疾病的风险，并且其中如果确定的Pro-脑啡肽或其片段的水平高于所述预先确定的 pENK阈值，则该受试者被鉴定为不具有增加的不利事件的风险或在激素替代疗法的情况下不具有增强的吸引疾病的风险。

公开(公告)号：EP2369350B1

公开(公告)日：2014-08-20

申请号：EP11165586.6

申请日：2005-04-20

申请人： SphingoTec GmbH

发明人： Bergmann, Andreas ,  Sparwasser, Andrea (geb. Ernst)

IPC分类号： G01N33/68 ,  G01N33/50

CPC分类号： G01N33/68 ,  G01N33/6872 ,  G01N2410/06 ,  G01N2500/04

公开(公告)号：EP2369350A2

公开(公告)日：2011-09-28

申请号：EP11165586.6

申请日：2005-04-20

申请人： SphingoTec GmbH

发明人： The designation of the inventor has not yet been filed

IPC分类号： G01N33/68 ,  G01N33/50

CPC分类号： G01N33/68 ,  G01N33/6872 ,  G01N2410/06 ,  G01N2500/04

摘要： The invention relates to the diagnosis components in human or animal body fluids, tissues and/or biomaterials. More specifically the invention relates to the use of protachykinin and/or its fragments isolated from body fluids, tissues or other biomaterials as a marker peptide for medical diagnostics as well as for the diagnostic detection of the course prognosis and course control of diseases/disorders of the central nervous system, comprising Alzheimer's disease, Parkinson's dis-ease, depression and/or conditions of pain, neurological, endocrinological, cerebral, muscular, local, systemic, chronic, inflammatory diseases, infectious diseases comprising bacterial and viral infections, meningitis, sepsis, Crohn's disease, colitis ulcerosa, sickle cell anemia, ischemia, amyotrophic lateral sclerosis, arthritis comprising rheumatoid arthritis, bronchitis, hyperalgesia, asthma, intoxi-cation comprising bacterial intoxication, immunological disorders, poly/-trauma comprising cranio-cerebral trauma, tumors/cancer, stroke, stress, atopis dermatitis, HIV, Huntington's disease, burns, schizophrenia, Hirschsprung's disease, allergies, familial dysautononmia (Riley Day syndrome), hematopoietic disorders, gliomas comprising glioblastomas and astrocytomas, disorders of the blood brain barrier. The invention further provides antibodies for binding to certain proteins and their fragments, more specifically protachykinin and its fragments. In accordance with the invention, a kit useful for the above-mentioned diagnosis is also provided.

摘要翻译： 本发明涉及在人或动物体液，组织和/或生物材料的诊断部件。 更具体地，本发明涉及使用protachykinin和/或其片段的从体液，组织或其它生物材料作为用于医疗诊断的标记物肽，以及用于的疾病/病症的过程中预后和过程控制的诊断检测中分离 中枢神经系统，包括阿耳茨海默氏病，帕金森氏病，抑郁症和/或疼痛，神经，内分泌，脑，肌肉，局部，全身，慢性，炎症性疾病的病症，感染性疾病包括细菌和病毒感染，脑膜炎，败血症 ，克罗恩氏病，溃疡性结肠炎，镰状细胞贫血症，局部缺血，肌萎缩性侧索硬化，关节炎，包括类风湿性关节炎，支气管炎，痛觉过敏，哮喘，中毒包含细菌中毒，免疫学疾病，聚/ -trauma包括颅脑外伤，肿瘤/ 癌症，中风，应激，atopis皮炎，HIV，亨廷顿氏病，烧伤，精神分裂症，HIRS chsprung氏病，过敏症，家族性dysautononmia（莱利Day综合征），造血功能障碍，神经胶质瘤，包括成胶质细胞瘤和星形细胞瘤，血脑屏障的疾病。 本发明提供了另外的抗体用于结合某些蛋白质及其片段，更具体地protachykinin及其片段。 在符合本发明雅舞蹈，对于上述的诊断有用的试剂盒因而提供。

公开(公告)号：EP1745297A1

公开(公告)日：2007-01-24

申请号：EP05742347.7

申请日：2005-05-11

申请人： SphingoTec GmbH

发明人： BERGMANN, Andreas ,  ERNST, Andrea

IPC分类号： G01N33/94 ,  C07K16/00

CPC分类号： C07K16/26 ,  G01N2333/70

摘要： The invention relates to the diagnosis of components in human or animal body fluids, tissues and/or biomaterials. More specifically the invention relates to the use of precursors of enkephalins and/or its fragments isolated from body fluids, tissues or other biomaterials as marker peptide or medical diagnositics as well as for the diagnostic detection of the course prognosis and course control of diseases/disorders comprising diseases/disorders of the central nervous system, neurodegenerative diseases, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, ischemia comprising myocardiac ishcemica, schizophrenia, diseases/disorders of the immune system, diseases/conditions of pain, chronic pain, migraine, tension type headache, tumor diseases/cancer comprising lymphoblastic leukaemia, malignant brain tumors, adenomas, in particular human pituitary adenomas, disorders of the blood brain barrier, multiple sclerosis, inflammation, chronic arthritis, infectious diseases, bacterial and viral infections, in particular infections of Gram-positive bacteria, borna diseases virus infections, peritonitis, intoxication, AIDS, stress, trauma comprising head trauma, infarction, in particular cerebral infarction, heart and cardiovascular diseases comprising coronary heart disease, bone and skin disorders, malaria chronic/obstructive pulmonary disease and cerebral damage. The invention further provides antibodies ofr binding to certain proteins and their fragments, more specifically proenkephalin and its fragments. In accordance with the invention, a kit useful for the above mentioned diagnosis is also provided.

公开(公告)号：EP3631459A1

公开(公告)日：2020-04-08

申请号：EP18725873.6

申请日：2018-05-29

申请人： SphingoTec GmbH

发明人： BERGMANN, Andreas

IPC分类号： G01N33/68

公开(公告)号：EP2823316B1

公开(公告)日：2018-05-23

申请号：EP13708803.5

申请日：2013-03-08

申请人： sphingotec GmbH

发明人： BERGMANN, Andreas ,  MELANDER, Olle

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N2333/4706 ,  G01N2800/042

摘要： Subject matter of the present invention is a method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject wherein said subject is non-diabetic, comprising the following steps determining the level of pro-neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of pro-neurotensin or fragments thereof with the risk of said subject for contracting diabetes mellitus and/or metabolic syndrome, wherein an elevated level is predictive for an enhanced risk of getting diabetes mellitus and/or metabolic syndrome, or wherein an elevated level correlates to the diagnosis of metabolic syndrome in a subject wherein said subject is non-diabetic.

公开(公告)号：EP3201631A1

公开(公告)日：2017-08-09

申请号：EP15771608.5

申请日：2015-10-01

申请人： SphingoTec GmbH

发明人： BERGMANN, Andreas ,  MELANDER, Olle ,  NG, Leong

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N2333/72 ,  G01N2800/50 ,  G01N2800/52

摘要： A method of determining whether a subject has a vascular risk that can be reduced by blood pressure lowering therapy with antihypertensive drugs (e.g. Angiotensin converting enzyme inhibitor (ACE inhibitor), Angiotensin Receptor Blocker (ARB), Beta-Adrenoreceptor Blocker (Beta-blocker) and/or statins) by determining the level of hGH, and/or its isoforms in a blood sample of said subject and comparing the determined level of hGH, and/or its isoforms in said blood sample with a pre-determined threshold.

摘要翻译： 本发明的主题是确定受试者是否具有可以通过降压药降血压疗法（例如血管紧张素转换酶抑制剂（ACE抑制剂），血管紧张素受体阻断剂（ARB），β-受体阻滞剂， 包括以下步骤：·确定所述受试者的血液样品中的hGH和/或其同种型的水平，和·将所确定的hGH和/或其同种型的水平与 所述血液样品具有预定的阈值，并且其中如果所确定的hGH水平和/或其同种型高于所述预定阈值，则所述受试者被鉴定为具有血管风险，所述血管风险可以通过降低血压 （例如血管紧张素转化酶抑制剂（ACE抑制剂），血管紧张素受体阻断剂（ARB），β-肾上腺受体阻断剂（β-阻断剂）和/或他汀类药物） 如果所确定的hGH水平和/或其同种型低于所述预定阈值，那么所述受试者被鉴定为不具有血管风险，所述血管风险可以通过使用抗高血压药物（例如抗高血压药）进行降血压治疗而降低。 血管紧张素转换酶抑制剂（ACE抑制剂），血管紧张素受体阻断剂（ARB），β-肾上腺素受体阻断剂（β-阻滞剂）和/或他汀类药物）。